rHuEPO in the treatment of postpartum anemia: subcutaneous versus intravenous administration.
The aim of this study was to determine whether single-shot therapy with recombinant human erythropoietin (rHuEPO) is as effective as divided dosing in postpartum anemia for both subcutaneous and intravenous administration. In a randomized prospective study we treated 95 women with postpartum anemia (Hb < 10 g/dl) within 72 h after delivery with rHuEPO (total dose 300 U/kg body weight) and oral iron supplementation in four treatment groups: group A rHuEPO 150 U/kg s.c. once daily for two consecutive days; group B rHuEPO 150 U/kg i.v. once daily for two consecutive days; group C rHuEPO 300 U/kg s.c. once only; group D rHuEPO 300 U/kg i.v. once only. No significant intergroup differences were found in the mean increase of hemoglobin (P = 0.93 for a difference of 1 g/dl). The mean increase in the single-shot groups was 3 g/dl in 14 days. There was a significant reduction of iron stores in all groups. We conclude that single-shot rHuEPO 300 U/kg body weight corrects anemia just as effectively as divided doses on both intravenous and subcutaneous administration. The overall increase in Hb is only slight but preliminary results indicate that the effect can be enhanced by administrating iron intravenously and by an interval therapy with high-dose rHuEPO.
Zimmermann
R
R
Department of Obstetrics, University Hospital of Zurich, Switzerland.
Breymann
C
C
Huch
R
R
Huch
A
A
D000328:Adult; D000740:Anemia / Q000188:drug therapy*; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D011446:Prospective Studies; D011644:Puerperal Disorders / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage
D011994:Recombinant Proteins; D004921:Erythropoietin